A Randomized Open-Label Study of Relugolix  Alone or Relugolix Combination Therapy in Premenopausal Women

ConclusionsRelugolix 40 mg in combination with E2 1 mg and NETA 0.5 mg provided systemic E2 concentrations within a range expected to minimize the risk of undesirable effects of hypoestrogenism associated with the administration of relugolix alone.Clinical Trial RegistrationClinicaltrials.gov identifier no. NCT04978688. Trial registration date: 27 July, 2021; retrospectively registered.
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research